Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Report: Glaxo To Cut Prices For Poor Countries

By Pharmaceutical Processing | February 17, 2009

NEW YORK (AP) — Drug maker GlaxoSmithKline PLC says it will cut drug prices to the 50 poorest countries in the world and use 20 percent of its profits from those countries to build health clinics and other infrastructure, according to published reports. The company’s chief executive, Andrew Witty, also is proposing that drug companies, nonprofit groups and others donate their patents related to neglected tropical diseases to a common pool that could be used to speed development of new drugs, the Wall Street Journal said. Witty said prices will be cut for the poorest countries so that they are no higher than 25 percent of the price in developed countries, according to the report. Glaxo, the second biggest drug maker by sales, generates about $43 million annually in revenue from those countries. About $1.5 million to $2.5 million would be generated for the clinics, Witty told the Journal. HIV drugs are already sold at not-for-profit prices in those countries, but the prices will be cut if the drugs aren’t already sold at prices below the threshold of 25 percent, reports said. Treatments for hepatitis B, genital herpes, malaria and asthma are expected to be among those affected by the plan. Witty told the Journal that Glaxo will not contribute its HIV patents to the pool. The company believes there already is innovation in HIV medicines because of the profit that can be made in Western markets.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE